title: Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.
abstract: A 13-valent pneumococcal conjugate vaccine (PCV13), developed with the same chemistry used for the 7-valent PCV vaccine (PCV7) and with the goal of expanding serotype coverage, was clinically evaluated in the United States and Europe and found to induce capsular-specific antibody responses comparable to those of PCV7 for the common serotypes, with robust responses to the 6 additional serotypes. In addition, PCV13 has a similar safety profile to PCV7 and can be given routinely to infants and children, ideally as a 3-dose primary series in the first year of life, with a booster dose in the second year. Children who have initiated their vaccination program with PCV7 can transition to PCV13 at any point in the schedule. Children aged ≥15 months who have been completely vaccinated with PCV7 can receive a single dose of PCV13 to induce immunity to the 6 additional serotypes.
authors.affiliation: Pfizer Vaccines, Collegeville, Pennsylvania, USA. peter.paradiso@pfizer.com
authors.forename: Peter R
authors.initials: PR
authors.lastname: Paradiso
mesh_terms: D002675:Child, Preschool; D005060:Europe / Q000453:epidemiology; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods; D007223:Infant; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D014481:United States / Q000453:epidemiology; D014611:Vaccination / Q000379:methods
chemical_list: C538862:13-valent pneumococcal vaccine; D022242:Pneumococcal Vaccines